BFRI Biofrontera Inc.

FDA Catalyst Company
2.65
+0.03  (+1%)
Previous Close 2.62
Open 2.74
52 Week Low 2.2
52 Week High 14.63
Market Cap $45,327,585
Shares 17,104,749
Float 9,104,749
Enterprise Value $78,278,154
Volume 196,093
Av. Daily Volume 2,224,154
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
Benchmark Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 12/15/2021
Roth Capital Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 11/24/2021

Latest News

  1. WOBURN, MA., May 16, 2022 (GLOBE NEWSWIRE) -- Biofrontera, Inc. (NASDAQ:BFRI, BFRIW))), announced today that it has entered into a securities purchase agreement with a single institutional investor for the purchase of 3,419,000 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 3,419,000 shares of common stock, in a private placement. The purchase price for one share of common stock (or common stock equivalent) and a warrant to purchase one share of common stock is $2.75. The warrants have an exercise price of $2.77 per share, will be exercisable six months after issue date, and will expire five and one-half years from the issuance date.

    Roth Capital Partners and The…

    View Full Article
  2. Conference call begins at 11:00 a.m. Eastern time today

    WOBURN, Mass., May 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced financial results for the three months ended March 31, 2022, and provided a business update.

    Financial Highlights & Recent News

    • Total revenues for the first quarter of 2022 were $9.8 million, an increase of 106% from the first quarter of 2021
    • Cash and cash equivalents were $22.4 million as of March 31, 2022, compared with $24.5 million as of December 31, 2021
    • Created a dedicated key accounts team to address the changing landscape of the dermatology industry, and advanced plans…
    View Full Article
  3. WOBURN, Mass., May 06, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, will report financial results for the three months ended March 31, 2022 before the opening of the U.S. financial markets on Friday, May 13, 2022 and will hold a conference call that same day beginning at 11:00 a.m. Eastern time to discuss those results, provide a business update and answer questions.

    Conference Call and Webcast Information

    Event:Biofrontera Inc. First Quarter 2022 Financial Results and Business Update Conference Call
    Date:Friday, May 13, 2022
    Time:11:00 a.m. Eastern time
    Conference call:1-877-877-1275 (U.S.)
    1-412-858-5202 (international)
    Webcast:Live
    View Full Article
  4. Live Demonstration of New RhodoLED® XL to be Featured

    WOBURN, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today its sponsorship of the 17th Edition of the Music City Symposium for Cosmetic Advances & Laser Education (SCALE), being held May 11-15, 2022 in Nashville, Tenn. As a Sponsor, Biofrontera will be hosting a booth showcasing its innovative, FDA-approved products and featuring its new RhodoLED® XL illumination lamp used in photodynamic therapy (PDT) for treating actinic keratosis (AK). On Saturday, May 14, 2022, Dr. Michael Gold, M.D., a board-certified dermatologist, cosmetic surgeon and founder of Gold…

    View Full Article
  5. Ameluz® for the treatment of actinic keratoses now at www.ameluz.com
    Xepi® for the treatment of impetigo now at www.xepicream.com

    WOBURN, Mass. , April 21, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today the launch of new and updated websites for its two products, Ameluz® and Xepi®. Now each brand has two websites in one featuring a patient-focused and a healthcare professional (HCP)-focused website with appropriate content for both audiences.

    To view the new websites, please visit www.ameluz.com for Ameluz® or www.xepicream.com for Xepi®.

    "A full team of Biofrontera employees provided multidisciplinary…

    View Full Article
View All Biofrontera Inc. News